Nakhaei Karim, Jalilian Habib, Arab-Zozani Morteza, Heydari Somayeh, Torkzadeh Leila, Taji Masoomeh
Department of Accounting, Islamic Azad University Birjand Branch, Birjand, Iran.
Department of Health Services Management, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Health Policy Technol. 2021 Dec;10(4):100572. doi: 10.1016/j.hlpt.2021.100572. Epub 2021 Nov 8.
This study aimed to estimate the cost of COVID-19 patients and some affecting factors in Iran.
This was a prevalence-based cost-of-illness study based on a bottom-up costing approach which was conducted from March 2020 to July 2020 Data were extracted from the hospital's Hospital Information System (HIS) and Cost-of-illness (COI) assessment checklist. Indirect costs were assessed based on the Human Capital Approach. Data were analyzed using SPSS software version 22 and Microsoft EXCEL 2016.
A total of 745 Covid-19 patients were included in the analysis. The mean total cost was estimated at 8813.15 (PPP, Current International $), accounting for 60% of GDP per capita. The mean direct and indirect cost was 3362.49 (PPP, Current International $) (38% of the total cost and 23% of the GDP per capita), and 5450.66 (PPP, Current International $) (62% of the total cost and 37% of the GDP per capita), respectively. The mean hospitalization cost was higher among patients who died and those who were covered by supplemental insurance. Also, the costs of disease experienced a dramatic rise with increasing age. For different scenarios in terms of outbreak rate, hospitalization rate and mortality rate, the total estimated cost of illness for Covid-19 ranged from 6263 million (PPP, Current International $) to 63,474 million (PPP, Current International $).
Covid-19 imposes a substantial financial burden on people, health care systems, insurance organizations and the country's economy as a whole. Since the economic burden of this disease increases dramatically by increasing disease outbreak, more attention should be paid to the development and implementation of appropriate preventive programs.
本研究旨在估算伊朗新冠肺炎患者的成本及一些影响因素。
这是一项基于患病率的疾病成本研究,采用自下而上的成本核算方法,研究时间为2020年3月至2020年7月。数据从医院的医院信息系统(HIS)和疾病成本(COI)评估清单中提取。间接成本基于人力资本法进行评估。使用SPSS 22版软件和Microsoft EXCEL 2016对数据进行分析。
共有745名新冠肺炎患者纳入分析。平均总成本估计为8813.15(购买力平价,当前国际美元),占人均国内生产总值的60%。平均直接成本和间接成本分别为3362.49(购买力平价,当前国际美元)(占总成本的38%和人均国内生产总值的23%)和5450.66(购买力平价,当前国际美元)(占总成本的62%和人均国内生产总值的37%)。死亡患者和参加补充保险的患者的平均住院成本更高。此外,疾病成本随着年龄的增长而急剧上升。对于不同的疫情爆发率、住院率和死亡率情景,新冠肺炎的疾病总成本估计在6.263亿(购买力平价,当前国际美元)至634.74亿(购买力平价,当前国际美元)之间。
新冠肺炎给个人、医疗保健系统、保险机构以及整个国家的经济带来了沉重的财政负担。由于这种疾病的经济负担会随着疾病爆发的增加而急剧上升,因此应更加重视制定和实施适当的预防方案。